After going through the DSP healthcare portfolio, I find only 8% equity exposure to American Pharma Companies…please correct me if I am wrong…
Abbott Lab 3%
Intuitive surgical Inc 2.8%
Abiomed Inc 2.5%
I should have written upto 25%. I have seen it more than 10% once. Basically, they have a provision to invest upto 25% but at the moment, it might have found better opportunities in India or they might be conserving some cash to deploy on the right opportunity like Covid-19 vaccine.You can find more information in their scheme documents as well.
The cash is 6% here and also their investment style is Mid-cap growth which I feel will give superior return in a sector tailwind scenario compared to risk.
Not denying what you are saying. It is no.1 Healthcare fund in India returning 73% during last one year having beaten not only the pharma index but all its Peers also by a wide margin.
But one need to be careful while investing in any sectoral fund , though Pharma seems to be a safer play considering the tailwinds the sector has which is expected to continue post covid19 according to most analysts !
People just can not neglect their health !
True. This is the only thematic fund I have. I will be stopping SIP in it soon. I understand the risks in thematic funds.
@Southern_Cross why are you planning to stop? Arent the tailwinds still there?
I look at my portfolio level and take decisions. Pharma is constituting 24% of my portfolio at the moment for me and it is not a good idea to invest more into one sector alone.
Updated Stock Portfolio
- Exited ITC@198 and added Transpek after quarterly results.
- Exited JB Chemicals@1050
- Reduced stake in Manappuram and accumulated existing holdings in pharma and chemical basket.
- Added Vedanta, hoping 20%+ profit there.
- Momentum: Booked profits in UPL and Coromandel. Added Excel and Astek Life.
3 Likes
I like the PF because of the weightage to pharma (specially API) and chemicals…I have also 40% allocation to these 2 sectors and riding on the momentum…have many stocks in these 2 sectors common with you…hope the juggernaut in these sectors continue for long and reward us handsomely.
2 Likes
Updated Stock Portfolio
Overall strategy remains same, trying to consolidate positions based on Q earnings
Accumulating
- Alembic, Biocon, Jubliant
- Transpek, DeepakNit
- Astec
- Radico
- Polycab
- Kovai
Added
- ITC
Booked Profits in
- HindZinc, Excel
Booked loss in Vedanta
1 Like
Booked Profit
- entirely in AartiInd@1150. It’s almost a ~3 bagger for me but sold as I felt that there are better opportunities at current price levels and wanted to book profits. I’ll enter again when I can valuation comfort.
- entirely in ITC@190 as it was a short term bet.
- partially in Biocon@440 due to valuations, but may raise my position again if it comes below 360
Accumulating
- Transpek
- NATCO
- Laurus
- Jubliant Life
Entered
- Birla Corp, SIS, MCDowells as short term bets (<3 months view) based on valuation and results
3 Likes
Booked Profit
- partially in AlkylAmine @~4800 as I’m not comforatble with the valuation, P/S is ~10 now. But good businsess so will add when price comes down
- entirely in SHK @~140 as I allocated more in my existing holdings where my conviction is higher
- entirely in Trading bets with decent profits.
Sold
- Astec @~1180 with marginal loss as I allocated more in my existing holdings where my conviction is higher
- Astec with marginal loss as I allocated more in my existing holdings where my conviction is higher
Accumulating following on falls using money aquired from sale of stocks.
- Laurus
- Neuland
- Sequant
- Kovai
- Polycab
- DeepakNit
- Transpek
No capital infusion in the last 3 months, just moving money around within portfolio.
6 Likes
Booked Profit
- entirely in Alembic @~960, Natco @~ 935 and Aarti drugs @~660 to increase my allocation in bets where future earning visibility is better.
Booked Loss
- partially in Transpek @~1500 after disappointing Q3 results. I will increase my holding again if it comes down to attractive price.
Entered
- again into Astec @1050 post disappointing Q3 results as price seems attractive when considering future prospectus.
Accumulating following stocks slowly
- Laurus
- Neuland
- Syngene
- Jubliant
- Deepak Nitrite
- Dyn Products
- Kovai Med
- Polycab
No fresh capital infusion in the last 4 months, just moving money around within portfolio.
4 Likes
Booked Profit
- entirely in Solara @1263. No reason, just trying to concentrate my bets and reduce pharma exposure by shifting some money chemical basket.
Accumulating following stocks
- Astec
- Jubliant
- Kovai
- Laurus
Fresh capital infusion is trivial, accumulations are through sell transactions.
3 Likes
- Sold Jubliant Pharmova and bought Jubliant Ingrevia and future potential is relativelt high for the later
- Sold Alkyl and bought Balaji Amines, as valuation was relativelty favourable.
- Sold Transpek as found better opportunities in market, might enter again when the delived results.
- Sold Fairchem Organics as the holding % was ingsignificant and didn’t want to add more
- Sold KMC Spec at ~Rs 70 (a 5 bagger) and inclreased stake in other portfolio stocks as valuations is high in the former and not comfortable to accoumlate
- Sold NATIONALUM at ~Rs 100 (3 bagger) and increased stake in Maithan Alloy as later is fundamentally better company in a cyclical sector.
Accumlating Sequent, CanFin, Manappuram, Somany, SIS, Praj on dips.
New entered in bunch of realEstate and Infra stocks. Mostly through proxy play companies.
1 Like